| Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ... New England Journal of Medicine 378 (12), 1107-1120, 2018 | 940 | 2018 |
| Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ... Annals of Oncology 32 (1), 23-33, 2021 | 890 | 2021 |
| Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial M Wang, S Rule, PL Zinzani, A Goy, O Casasnovas, SD Smith, G Damaj, ... The Lancet 391 (10121), 659-667, 2018 | 414 | 2018 |
| Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial JC Byrd, P Hillmen, P Ghia, AP Kater, A Chanan-Khan, RR Furman, ... Journal of clinical oncology 39 (31), 3441, 2021 | 393 | 2021 |
| miR-34a as part of the resistance network in chronic lymphocytic leukemia T Zenz, J Mohr, E Eldering, AP Kater, A Bühler, D Kienle, D Winkler, ... Blood, The Journal of the American Society of Hematology 113 (16), 3801-3808, 2009 | 348 | 2009 |
| Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up … AP Kater, JF Seymour, P Hillmen, B Eichhorst, AW Langerak, C Owen, ... Journal of Clinical Oncology 34 (4), 269-277, 2019 | 332 | 2019 |
| ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia S Pospisilova, D Gonzalez, J Malcikova, M Trbusek, D Rossi, AP Kater, ... Leukemia 26 (7), 1458-1461, 2012 | 287 | 2012 |
| A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European … AC Rawstron, C Fazi, A Agathangelidis, N Villamor, R Letestu, ... Leukemia 30 (4), 929-936, 2016 | 264 | 2016 |
| COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ... Leukemia 34 (9), 2354-2363, 2020 | 260 | 2020 |
| Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact P Baliakas, S Jeromin, M Iskas, A Puiggros, K Plevova, F Nguyen-Khac, ... Blood, The Journal of the American Society of Hematology 133 (11), 1205-1216, 2019 | 236 | 2019 |
| Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity LA Smit, DYH Hallaert, R Spijker, B de Goeij, A Jaspers, AP Kater, ... Blood 109 (4), 1660-1668, 2007 | 217 | 2007 |
| ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation J Malcikova, E Tausch, D Rossi, LA Sutton, T Soussi, T Zenz, AP Kater, ... Leukemia 32 (5), 1070-1080, 2018 | 215 | 2018 |
| Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study AP Kater, JQ Wu, T Kipps, B Eichhorst, P Hillmen, J D’rozario, S Assouline, ... Journal of Clinical Oncology 38 (34), 4042, 2020 | 190 | 2020 |
| A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi R Hoogeboom, KPM van Kessel, F Hochstenbach, TA Wormhoudt, ... Journal of Experimental Medicine 210 (1), 59-70, 2013 | 182 | 2013 |
| p53-dependent non-coding RNA networks in chronic lymphocytic leukemia CJ Blume, A Hotz-Wagenblatt, J Hüllein, L Sellner, A Jethwa, T Stolz, ... Leukemia 29 (10), 2015 | 181 | 2015 |
| IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells MF Pascutti, M Jak, JM Tromp, IAM Derks, EBM Remmerswaal, ... Blood, The Journal of the American Society of Hematology 122 (17), 3010-3019, 2013 | 172 | 2013 |
| c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches DYH Hallaert, A Jaspers, CJ van Noesel, MHJ van Oers, AP Kater, ... Blood, The Journal of the American Society of Hematology 112 (13), 5141-5149, 2008 | 158 | 2008 |
| Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors R Thijssen, E Slinger, K Weller, CR Geest, T Beaumont, MHJ Van Oers, ... Haematologica 100 (8), e302, 2015 | 151 | 2015 |
| Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy JAC van Bruggen, AWJ Martens, JA Fraietta, T Hofland, SH Tonino, ... Blood, The Journal of the American Society of Hematology 134 (1), 44-58, 2019 | 149 | 2019 |
| Suppression of Glut1 and glucose metabolism by decreased Akt/mTORC1 signaling drives T cell impairment in B cell leukemia PJ Siska, GJW van der Windt, RJ Kishton, S Cohen, W Eisner, NJ MacIver, ... The Journal of Immunology 197 (6), 2532-2540, 2016 | 146 | 2016 |
